SCHEMBL13833541

SCHEMBL13833541

Cc1cccc2c1CNC=C2

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.47
PARP10 Q53GL7 1/20 0.33
PARP11 Q9NR21 1/20 0.33
HTR2C P28335 1/20 0.32
HTR5A P47898 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2A6 P11509 1/20 0.31
ACHE P22303 1/20 0.31
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA7 P43166 1/20 0.30
CA9 Q16790 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18286330 0.80 RAPGEF4 (0.38) PARP1ALDH1A1
SCHEMBL19521462 0.76 PARP1 (0.47) PARP1PARP10PARP11ALDH1A1
SCHEMBL20124440 0.71 PARP1 (0.32) PARP1HTR2C
SCHEMBL4202677 0.71 PARP1 (0.42) PARP1CA1CA2CA7CA9
SCHEMBL30284510 0.69 TRPA1 (0.41) PARP1ALDH1A1
SCHEMBL4854314 0.68 SLC6A2 (0.37) PARP1PARP10PARP11HTR2CHTR5A
SCHEMBL22792850 0.67 PARP1 (0.34) PARP1
SCHEMBL29429329 0.66 PARP1 (0.95) PARP1HTR2CCA1CA2CA9
SCHEMBL33931 0.66 PARP1 (0.95) PARP1HTR2CCA1CA2CA9
SCHEMBL5017835 0.65 PARP1 (0.44) PARP1CYP1A2CYP2A6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2708540-B1 PYRIMIDO-DIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-07-25 EP disclosed
CN-103214471-B The preparation method of compound with Na-dependent glucose transporter inhibitory activity 田边三菱制药株式会社 2018-02-06 CN disclosed
US-9453021-B2 Pyrimidodiazepinone compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-09-27 US disclosed
US-9453021-B2 Pyrimidodiazepinone compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-09-27 US disclosed
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-06-19 US disclosed
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-06-19 US disclosed
EP-2708540-A1 PYRIMIDO-DIAZEPINONE COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2014-03-19 EP disclosed
WO-2012153796-A1 PYRIMIDO-DIAZEPINONE COMPOUND 協和発酵キリン株式会社 (JP) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND REN, AGTR1, KCNJ1 PARP1 2206/4885PARP10 1765/4885PARP11 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.